3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
14
Fallopian Tube Neoplasms
13
Carcinoma, Ovarian Epithelial
7
Prostatic Neoplasms
5
Endometrial Neoplasms
5
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
2
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Genital Neoplasms, Male
1
Esophageal Neoplasms
1
Interventions
Filgrastim
15
Carboplatin
10
Ifosfamide
9
Doxorubicin
9
Cyclophosphamide
9
Peripheral Blood Stem Cell Transplantation
7
pembrolizumab
6
Radiotherapy
6
Gemcitabine
6
Temozolomide
5
Etoposide
5
Cisplatin
5
Paclitaxel
4
Docetaxel
4
Amifostine
4
aldesleukin
3
aflibercept
3
Trastuzumab
3
Specimen Handling
3
Radiosurgery
3
Psychiatric Rehabilitation
3
Magnetic Resonance Spectroscopy
3
Biopsy
3
tislelizumab
2
sodium thiosulfate
2
selinexor
2
pazopanib
2
palbociclib
2
etoposide phosphate
2
eribulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
rucaparib
×
Gynecologic
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts